Navigation Links
Genta Receives Key Patent Related to Oral Gallium Compound G4544
Date:4/14/2008

Company to Seek Buyer for Marketed Parenteral Product Ganite(R)

BERKELEY HEIGHTS, N.J., April 14 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA) today announced that the Company has received notice that its patent application covering novel pharmaceutical gallium compositions and complexes has been allowed by the U.S. Patent Office. Issued U.S. Patent 7,354,952 extends the intellectual property surrounding the Company's franchise of oral gallium-containing products that are intended as potential treatment for diseases associated with accelerated bone loss. The lead compound in this investigational pipeline, G4544, was developed in collaboration with Emisphere Technologies, Inc. (Nasdaq: EMIS) and has completed its initial Phase 1 dose-ranging study. Results of this study will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) that takes place in Chicago, IL from May 30-June 3, 2008.

With continued progress in the oral formulation program, the Company has elected to seek a buyer for the intravenous formulation of its on-market product from this franchise, Ganite(R) (gallium nitrate injection). The active ingredient in both Ganite and G4544 is ionic gallium, which is reversibly incorporated into bone where its acts as a potent inhibitor of bone resorption and possibly as a mild anabolic agent to enhance bone formation. Ganite is approved by the U.S. Food and Drug Administration for treatment of patients with cancer-related hypercalcemia that is resistant to hydration
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
(Date:6/30/2015)... , June 24, 2015 Research ... of the "Global Endoscopy Devices Market 2015-2019" ... global endoscopy devices market to grow at a ... The global endoscopy devices market can be segmented ... accessories, and services. The market can be further ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3
... (Nasdaq: ISIS ), the leader in antisense therapeutics, ... Stifel Nicolaus, Healthcare Conference 2011 on Thursday, September 08, 2011 ... Boston. A live audio webcast of the presentation ... the Company,s Web site, www.isispharm.com .  A replay of ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... Company,s participation at the William Blair and Company 5th Annual ... Hotel in New York City on September 8, 2011. ... Research and Development, will present on Thursday, September 8, 2011 ...
Cached Medicine Technology:Sequenom Announces Participation at William Blair and Company 5th Annual Emerging Growth Stock Conference 2
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview ... more than doubled the size of its medical staff to further enhance its ... which includes physicians, nurse practitioners and physician assistants -- now totals 17, compared ...
(Date:6/30/2015)... Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Techniques, they will be wowed with the incredible care that they receive and the ... care for their patients; but now they are proud to offer the same experience, ...
(Date:6/30/2015)... ... ... The U.S. Women's National Soccer Team will face the Costa Rica Women's National team ... August 16th at Heinz Field in Pittsburgh at 1:30 p.m. local time. On Wednesday, ... TN. , The USA WNT previously played at Heinz Field in Pittsburgh and won against ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... ... newest oncology centers are partnering to improve access to cancer prevention, screening and ... Cancer Center (LCC) have announced an affiliation that will see Roswell Park faculty ...
(Date:6/30/2015)... ... June 30, 2015 , ... After more than five years ... Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin of all ... 35, hits the market just in time to help protect the skin of all ...
Breaking Medicine News(10 mins):Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2
... Conference on Cell Therapy for Cardiovascular Disease sponsored ... comprehensive program dedicated to the evolving field of ... cardiac and vascular disease, as well as related ... conference will focus on preclinical and clinical studies ...
... The March of Dimes, along with its partners, are giving ... to learn from each other and to work together to ... give more babies a healthy start. U.S. Surgeon ... Prevention Symposium. The symposium will was a forum to share ...
... of researchers has discovered 13 new regions of the genome ... on the biological pathways involved in reproductive lifespan and will ... cancer and heart disease. Menopause is a ... in their early 50s. The timing of menopause can have ...
... Kathleen Doheny HealthDay Reporter , SUNDAY, Jan. ... genomic regions they believe are linked with breast cancer ... disease. All three newly identified areas "contain interesting ... clinical research," said researcher Douglas Easton, a professor of ...
... 2012) Research to Prevent Blindness (RPB) has awarded ... School, a $30,000 Medical Student Eye Research Fellowship. The award ... award will allow Ms. Shah to participate in research under ... Dr. Louis Pasquale in collaboration with Dr. Suzanne Freitag, Director ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Jan. ... moratorium on controversial research into a modified avian flu virus ... Although the investigators believe their research has a public ... others that the genetically altered virus could escape from labs ...
Cached Medicine News:Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:March of Dimes launches Prematurity Prevention Network 2Health News:March of Dimes launches Prematurity Prevention Network 3Health News:Genes and timing of menopause 2Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Scientists Agree to Delay Controversial Bird Flu Research 2Health News:Scientists Agree to Delay Controversial Bird Flu Research 3
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... 2.2 offers extremely high resolution treatment capability ... an exceptionally wide 78° field of view. ... critical evaluation of the optic nerve head ... of the macula and disc. Redesigned to ...
... for focal laser therapy and mid-to-far peripheral ... a realistic contour of the retinal concavity, ... entire posterior pole extending to the equator. ... dynamic movement on the globe, therefore increasing ...
... The Digital 1.0x Imaging Lens is optimized ... reduce glare and reflections during general diagnosis and ... view of the posterior pole and a sharper ... Digital 1.0 X Imaging Lens is also ideal ...
Medicine Products: